Seasonal Influenza Vaccines – 5EU Drug Forecast and Market Analysis to 2025

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$6995

Influenza, often referred to as the flu, is an acute infection caused by one of the three closely related viruses, designated as influenza Type A, B, and C. The infection’s rapid onset and potential for high morbidity and mortality, particularly in high-risk patient populations such as the elderly and young children, make prompt and effective treatment with antiviral medication very difficult. For these reasons, prophylactic vaccination is the preferred intervention for seasonal influenza. A quadrivalent formulation of Intanza Intradermal is anticipated to be launched in the EU, following the launch of quadrivalent Fluzone Intradermal in the US. The sales of quadrivalent Intanza Intradermal are expected to increase to $1.5m in 2025. Its growth will be driven by its improved immunogenicity in elderly patients compared to typical influenza vaccines and the increase in the size of Germany’s elderly population. *This is an on-demand report and will be delivered within 24 hrs. (excluding weekends) of the purchase.

Scope

Overview of Seasonal Influenza Vaccines including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

Detailed information on the key drugs in 5EU including product description, safety and efficacy profiles as well as a SWOT analysis.

Sales forecast for the top drugs in 5EU from 2015-2025.

Analysis of the impact of key events as well the drivers and restraints affecting 5EU Seasonal Influenza Vaccines market.

Reasons to Buy

Understand and capitalize by identifying products that are most likely to ensure a robust return

Stay ahead of the competition by understanding the changing competitive landscape for Seasonal Influenza Vaccines.

Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential

Make more informed business decisions from insightful and in-depth analysis of drug performance

Obtain sales forecast for drugs from 2015-2025 in 5EU.

Table of Contents

1Table of Contents

1.1List of Tables

1.2List of Figures

2Introduction

2.1Catalyst

2.2Related Reports

2.3Upcoming Related Reports

3Disease Overview

3.1Etiology and Pathophysiology

3.1.1Etiology

3.1.2Pathophysiology

3.1.3Symptoms and Prognosis

4Disease Management

4.1Seasonal Influenza Immunization Policy

4.1.1Immunization Recommendations and Most Frequently Administered Seasonal Influenza Vaccines

4.2France

4.2.1Influenza Immunization Recommendations and Policies

4.2.2Clinical Practice

4.3Germany

4.3.1Influenza Immunization Recommendations and Policies

4.3.2Clinical Practice

4.4Italy

4.4.1Influenza Immunization Recommendations and Policies

4.4.2Clinical Practice

4.5Spain

4.5.1Influenza Immunization Recommendations and Policies

4.5.2Clinical Practice

4.6UK

4.6.1Influenza Immunization Recommendations and Policies

4.6.2Clinical Practice

5Competitive Assessment

5.1Overview

5.2Product Profiles – Major Brands, Inactivated Vaccines

5.2.1Fluzone Quadrivalent

5.2.2Fluzone High-Dose

5.2.3Fluzone Intradermal

5.2.4Vaxigrip

5.2.5Fluarix Tetra

5.2.6Fluvirin

5.2.7Afluria

5.2.8Agrippal

5.3Product Profiles – Major Brands, Inactivated Vaccines (Adjuvanted)

5.3.1Fluad

5.4Product Profiles – Major Brands, Live-Attenuated Vaccines

5.4.1FluMist Quadrivalent

5.5Product Profiles – Major Brands, Cell Cultured Vaccines

5.5.1Flublok

5.5.2Flucelvax

5.6Other Seasonal Influenza Vaccines

5.6.1Influvac

5.6.2Minor Brands

6Unmet Needs and Opportunity Analysis

6.1Overview

6.2Higher Level of Public Awareness and Positive Perception of Influenza Vaccines

6.2.1Unmet Need

6.2.2Gap Analysis

6.2.3Opportunity

6.3Immunization Policies Targeting Children and Adolescents

6.3.1Unmet Need

6.3.2Gap Analysis

6.3.3Opportunity

6.4Enhanced Vaccine Efficacy in High-Risk Groups

6.4.1Unmet Need

6.4.2Gap Analysis

6.4.3Opportunity

6.5Vaccines Leveraging Innovative and Efficient Manufacturing Technologies

6.5.1Unmet Need

6.5.2Gap Analysis

6.5.3Opportunity

6.6Improving the Cost-Effectiveness of Influenza Vaccines

6.6.1Unmet Need

6.6.2Gap Analysis

6.6.3Opportunity

6.7Vaccines with Broader Influenza Strain Coverage

6.7.1Unmet Need

6.7.2Gap Analysis

6.7.3Opportunity

6.8Improved Vaccine Safety Profile

6.8.1Unmet Need

6.8.2Gap Analysis

6.8.3Opportunity

7Pipeline Assessment

7.1Overview

7.2Promising Vaccines in Clinical Development

7.2.1Seasonal Influenza VLP Vaccine

7.2.2VN-100

7.2.3Quadrivalent Seasonal Influenza VLP Vaccine

7.3Promising Vaccines in Early-Stage Development

7.3.1FLU-v

7.3.2M-001

7.3.3TAK-850

7.3.4VAX-2012Q

7.4Other Vaccines in Development Outside the 7MM

8Market Outlook

8.1France

8.1.1Forecast

8.1.2Key Events

8.1.3Drivers and Barriers

8.2Germany

8.2.1Forecast

8.2.2Key Events

8.2.3Drivers and Barriers

8.3Italy

8.3.1Forecast

8.3.2Key Events

8.3.3Drivers and Barriers

8.4Spain

8.4.1Forecast

8.4.2Key Events

8.4.3Drivers and Barriers

8.5United Kingdom

8.5.1Forecast

8.5.2Key Events

8.5.3Drivers and Barriers

9Appendix

9.1Bibliography

9.2Abbreviations

9.3Methodology

9.4Forecasting Methodology

9.4.1Vaccine Coverage

9.4.2Vaccines Included

9.4.3Key Launch Dates

9.4.4Influenza Vaccine Tender System Assumptions

9.4.5General Pricing Assumptions

9.4.6Individual Vaccine Assumptions

9.4.7Pricing of Pipeline Agents

9.5Primary Research – KOLs Interviewed for this Report

9.6Primary Research – Prescriber Survey

9.7About the Authors

9.7.1Analyst

9.7.2Therapy Area Director

9.7.3Epidemiologists

9.7.4Director of Epidemiology

9.7.5Global Director of Therapy Analysis and Epidemiology

9.8About GlobalData

9.9Disclaimer

Table

Table 1: Notable Influenza Pandemics

Table 2: Influenza Symptoms

Table 3: Seasonal Influenza Immunization Recommendation Agencies by Country, 2016

Table 4: Immunization Recommendations and Most Frequently Administered Seasonal Influenza Vaccines, 2016

Table 5: Country Profile – France

Table 6: Country Profile – Germany

Table 7: Country Profile – Italy

Table 8: Country Profile – Spain

Table 9: Country Profile – UK

Table 10: Leading Seasonal Influenza Vaccines, 2016

Table 11: Product Profile – Fluzone Quadrivalent

Table 12: Immunogenicity Profile of Fluzone Quadrivalent

Table 13: Local and Systemic AEs of Fluzone Quadrivalent

Table 14: Fluzone Quadrivalent SWOT Analysis, 2016

Table 15: Global Sales Forecast ($m) for Fluzone Quadrivalent, 2015–2025

Table 16: Product Profile – Fluzone High-Dose

Table 17: Immunogenicity of Fluzone High-Dose Compared with Fluzone

Table 18: Local and Systemic AEs of Fluzone High-Dose

Table 19: Fluzone High-Dose SWOT Analysis, 2016

Table 20: Global Sales Forecast ($m) for Fluzone High-Dose, 2015–2025

Table 21: Product Profile – Fluzone Intradermal

Table 22: Comparison of Fluzone Intradermal Quadrivalent Versus Fluzone Intradermal Trivalent

Table 23: Local andsystemic AEs of Fluzone Intradermal Quadrivalent

Table 24: Fluzone Intradermal Quadrivalent SWOT Analysis, 2016

Table 25: Global Sales Forecast ($m) for Fluzone/Intanza Intradermal, 2015–2025

Table 26: Product Profile – Vaxigrip

Table 27: Cumulative Incidence of Influenza Infection in Children

Table 28: Local and Systemic AEs of Vaxigrip

Table 29: Vaxigrip SWOT Analysis, 2016

Table 30: Global Sales Forecast ($m) for Vaxigrip, 2015–2025

Table 31: Product Profile – Fluarix Tetra

Table 32: Immunogenicity Profile of Fluarix Tetra

Table 33: Local and Systemic AEs of Fluarix Tetra

Table 34: Fluarix Tetra SWOT Analysis, 2016

Table 35: Global Sales Forecast ($m) for Fluarix Tetra, 2015–2025

Table 36: Product Profile – Fluvirin

Table 37: Immunogenicity of Fluvirin in Adults

Table 38: Local and Systemic AEs of Fluvirin

Table 39: Fluvirin SWOT Analysis, 2016

Table 40: Global Sales Forecast ($m) for Fluvirin, 2015–2025

Table 41: Product Profile – Afluria

Table 42: Immunogenicity of Afluria in Adults

Table 43: Local and Systemic AEs of Afluria

Table 44: Afluria SWOT Analysis, 2016

Table 45: Global Sales Forecast ($m) for Afluria, 2015–2025

Table 46: Product Profile – Agrippal

Table 47: Immunogenicity of Agrippal

Table 48: Local and Systemic AEs of Agrippal

Table 49: Agrippal SWOT Analysis, 2016

Table 50: Global Sales Forecast ($m) for Agrippal, 2015–2025

Table 51: Product Profile – Fluad

Table 52: Immunogenicity Comparison of Fluad Versus Agriflu

Table 53: Local and Systemic AEs of Fluad

Table 54: Fluad SWOT Analysis, 2016

Table 55: Global Sales Forecast ($m) for Fluad, 2015–2025

Table 56: Product Profile – FluMist Quadrivalent

Table 57: Noninferiority of FluMist Quadrivalent Compared with FluMist Trivalent

Table 58: AEs of FluMist Quadrivalent

Table 59: FluMist Quadrivalent SWOT Analysis, 2016

Table 60: Global Sales Forecast ($m) for FluMist Quadrivalent, 2015–2025

Table 61: Product Profile – Flublok

Table 62: Immunogenicity of Flublok compared with Fluzone and Fluzone High-Dose

Table 63: Local and Systemic AEs of Flublok

Table 64: Flublok SWOT Analysis, 2016

Table 65: Global Sales Forecast ($m) for Flublok, 2015–2025

Table 66: Product Profile – Flucelvax

Table 67: Immunogenicity of Flucelvax

Table 68: Local and Systemic AEs of Flucelvax

Table 69:Flucelvax SWOT Analysis, 2016

Table 70: Global Sales Forecast ($m) for Flucelvax, 2015–2025

Table 71: Summary of Other Marketed Seasonal Influenza Vaccines, 2016

Table 72: Unmet Need and Opportunity in Seasonal Influenza Vaccines, 2016

Table 73: Seasonal Influenza Vaccines – Late-Stage Pipeline, 2016

Table 74: Quadrivalent Versions of Marketed Vaccines

Table 75: Product Profile – Seasonal Influenza VLP Vaccine

Table 76: Seasonal Influenza VLP Vaccine SWOT Analysis, 2016

Table 77: Global Sales Forecast ($m) for Seasonal Influenza VLP Vaccine, 2015–2025

Table 78: Product Profile – VN-100

Table 79: Comparison of Immunogenicity Profile of VN-100 and Subcutaneous Standard Vaccine

Table 80: Frequency of Local and Systemic AEs of VN-100 Compared with a Comparator Subcutaneous Vaccine

Table 81: VN-100 SWOT Analysis, 2016

Table 82: Global Sales Forecast ($m) for VN-100, 2015–2025

Table 83: Product Profile – Quadrivalent Seasonal Influenza VLP Vaccine

Table 84: Quadrivalent Seasonal Influenza VLP Vaccine SWOT Analysis, 2016

Table 85: Global Sales Forecast ($m) for Quadrivalent Seasonal Influenza VLP Vaccine, 2015–2025

Table 86: Promising Vaccines in Early-Stage Development, 2016

Table 87: Summary of Seasonal Influenza Vaccines in Development Outside the 7MM, 2016

Table 88: Sales Forecasts ($m) for Seasonal Influenza Vaccines in France, 2015 –2025

Table 89: Key Events Impacting Sales for Seasonal Influenza in France, 2015?2025

Table 90: France Seasonal Influenza Vaccines Market – Drivers and Barriers, 2015?2025

Table 91: Sales Forecasts ($m) for Seasonal Influenza Vaccines in Germany, 2015 –2025

Table 92: Key Events Impacting Sales for Seasonal Influenza in Germany, 2015?2025

Table 93: Germany Seasonal Influenza Vaccines Market – Drivers and Barriers, 2015?2025

Table 94: Sales Forecasts ($m) for Seasonal Influenza Vaccines in Italy, 2015–2025

Table 95: Key Events Impacting Sales for Seasonal Influenza in Italy, 2015?2025

Table 96: Italy Seasonal Influenza Vaccines Market – Drivers and Barriers, 2015?2025

Table 97: Sales Forecasts ($m) for Seasonal Influenza Vaccines in Spain, 2015 –2025

Table 98: Key Events Impacting Sales for Seasonal Influenza in Spain, 2015?2025

Table 99: Spain Seasonal Influenza Vaccines Market – Drivers and Barriers, 2015?2025

Table 100: Sales Forecasts ($m) for Seasonal Influenza Vaccines in the UK, 2015–2025

Table 101: Key Events Impacting Sales for Seasonal Influenza in the UK, 2015?2025

Table 102: UK Seasonal Influenza Vaccines Market – Drivers and Barriers, 2015?2025

Table 103: Key Launch Dates

Table 104: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

Figures

Figure 1: Influenza Virus Structure

Figure 2: Seasonal Influenza Vaccines – Phase II/Phase III Pipeline, 2016

Figure 3: Competitive Assessment of the Late-Stage Pipeline Vaccines for Seasonal Influenza, 2015–2025

Figure 4: Sales of Seasonal Influenza Vaccines by Class in France, 2015 and 2025

Figure 5: Sales of Seasonal Influenza Vaccines by Class in Germany, 2015 and 2025

Figure 6: Sales of Seasonal Influenza Vaccines by Class in Italy, 2015 and 2025

Figure 7: Sales of Seasonal Influenza Vaccines by Class in Spain, 2015 and 2025

Figure 8: Sales of Seasonal Influenza Vaccines by Class in the UK, 2015 and 2025

Frequently asked questions

Seasonal Influenza Vaccines – 5EU Drug Forecast and Market Analysis to 2025 thematic reports
Currency USD
$6,995

Can be used by individual purchaser only

$20,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Seasonal Influenza Vaccines – 5EU Drug Forecast and Market Analysis to 2025 in real time.

  • Access a live Seasonal Influenza Vaccines – 5EU Drug Forecast and Market Analysis to 2025 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.